Segment Reporting

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Segment Reporting

13.   Segment Reporting. We report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and OEM. Within these product categories, we sell a variety of products, including cardiology and radiology devices (which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases), as well as embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, breast cancer localization and guidance, biopsy, and interventional oncology and spine devices. Our endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. We evaluate the performance of our operating segments based on net sales and income from operations.

Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the three and six-month periods ended June 30, 2022 and 2021, were as follows (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2022		2021		2022		2021
Net sales
Cardiovascular	$	286,670	$	272,292	$	553,606	$	513,298
Endoscopy		8,306		8,033		16,785		15,940
Total net sales		294,976		280,325		570,391		529,238
Income from operations
Cardiovascular		21,275		6,777		34,401		18,978
Endoscopy		1,981		2,118		4,088		4,111
Total income from operations		23,256		8,895		38,489		23,089
Total other expense — net		(2,555)		(2,030)		(3,617)		(3,530)
Income tax expense		5,403		1,949		9,029		3,685
Net income	$	15,298	$	4,916	$	25,843	$	15,874